Schulman IRB Selected as National IRB for Cancer MoonShot
Schulman IRB will serve as the IRB of record for all participating research sites.
Schulman IRB has been selected as the national IRB for the Cancer MoonShot 2020 program.
The Cancer Moonshot 2020 coalition was formed to accelerate next generation immunotherapy and will design, initiate and complete randomized clinical trials at all stages of cancer in up to 20 tumor types in as many as 20,000 patients in multiple Phase I-III trials by the year 2020. Schulman IRB will serve as the IRB of record for all participating research sites. Schulman's IRB membership includes multiple oncologists and research professionals experienced in oncology research. These experts are led by an IRB Chair with extensive oncology experience in an institutional setting.
Read the full release.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
